Stem Cell Interneuron Purification via Fluorescent Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating large numbers of cortical or striatal immature interneuron precursor cells are inadequate for practical use in cell-based therapies for neurological and psychiatric disorders, such as epilepsy and Parkinson's disease, due to limitations in cell isolation and purification techniques.
Innovation Solution
A method involving the selection of a promoter and/or enhancer region specific to cortical or striatal immature interneuron precursor cells, followed by the introduction of a nucleic acid molecule encoding a marker protein, allowing for the separation of an enriched or purified population of these cells using fluorescence-activated cell sorting (FACS).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cell isolation methods are used, then the process is simple, but the purification precision of interneuron precursor cells is insufficient
Solution Approach 1:
The patent introduces a marker protein expression system before cell sorting, allowing cells to be pre-marked with fluorescent proteins (GFP, RFP, YFP) that indicate their identity as interneuron precursor cells. This preliminary action enables subsequent high-precision FACS sorting by fluorescence signal, achieving purification precision that would be impossible with conventional morphology-based methods alone.
Solution Approach 2:
The patent replaces conventional mechanical or manual cell sorting methods with fluorescence-activated cell sorting (FACS). Instead of relying on physical manipulation or visual inspection, the system uses fluorescent protein expression as a biological tag that can be detected optically and sorted automatically by flow cytometry, dramatically improving purification precision.
2Quantity of substance
If large numbers of interneuron precursor cells are required for therapy, then the quantity of cells must be increased, but current generation methods are inadequate
Solution Approach 1:
The patent uses embryonic stem cells as a universal starting material that can differentiate into multiple cell types, including the desired interneuron precursor cells. By establishing a standardized differentiation protocol from pluripotent stem cells, the system can generate large quantities of uniform, high-quality cells on demand, overcoming the limitations of primary cell isolation.
Solution Approach 2:
The patent employs controlled changes in culture conditions, growth factors, and differentiation parameters to guide stem cell development toward the interneuron precursor fate. By optimizing parameters such as retinoic acid concentration, sonic hedgehog signaling, and culture timing, the system achieves high-yield generation of pure cell populations suitable for therapeutic use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the isolation of a highly purified population of mammalian cortical or striatal immature interneuron precursor cells, characterized by their expression of Lhx6, which can be used for therapeutic applications, including transplantation to treat conditions mediated by interneuron dysfunction and as a delivery system for therapeutic agents.
Implementation Method 1
selecting a promoter and/or enhancer region which specifically functions in cortical or striatal immature interneuron precursor cells
Implementation Method 2
The cells expressing the marker protein are separated from the induced isolated population of cells, thereby isolating an enriched or purified population of cortical or striatal immature interneuron precursor cells
Data Source
AI summary
The present invention relates to methods of isolating a purified or enriched population of cortical or striatal immature interneuron progenitor cells and the isolated purified or enriched population of immature interneuron progenitor cells. Methods of treating a condition mediated by a loss or deficiency of interneuron function using the purified or enriched population of immature interneuron progenitor cells are also disclosed.